L Hefez1, K Zaghbib2,3, E Sbidian1,3,4,5, L Valeyrie-Allanore1,3, M Allain6, T A Duong1,3, A Colin1,3, F Bellivier7, H Romano1, N de Prost3,8,9, K Chazelas1,3, O Chosidow1,3,4,5, P Wolkenstein1,3,4, S Ingen-Housz-Oro1,3,4. 1. Department of Dermatology, AP-HP, Hôpitaux Universitaires Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, Créteil, F-94010, France. 2. Department of Psychiatry, AP-HP, Hôpitaux Universitaires Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, Créteil, F-94010, France. 3. Reference Center for Toxic Bullous Diseases, AP-HP, Hôpitaux Universitaires Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, Créteil, F-94010, France. 4. EA 7379 EpidermE, Université Paris-Est Créteil Val de Marne (UPEC), Créteil, F-94010, France. 5. Inserm, Centre d'Investigation Clinique 1430, Créteil, F-94010, France. 6. Clinical Research Unit, AP-HP, Hôpitaux Universitaires Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, Créteil, F-94010, France. 7. Department of Psychiatry and Addiction, AP-HP, GH Lariboisière - F. Widal, Paris, France. 8. Intensive Care Unit, AP-HP, Hôpitaux Universitaires Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, Créteil, F-94010, France. 9. CARMAS Research Group, Université Paris-Est Créteil Val de Marne (UPEC), Créteil, F-94010, France.
Abstract
BACKGROUND: Epidermal necrolysis is a rare and severe cutaneous adverse reaction to drugs with long-term somatic consequences and potentially underrecognized psychological complications. OBJECTIVES: To assess the prevalence and risk factors of post-traumatic stress disorder (PTSD) in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in a population of adults undergoing psychiatric evaluation. METHODS: In this prospective study, we included adult patients admitted at the acute phase of SJS/TEN to our dermatology department from June 2009 to February 2013. The main objective was to assess the prevalence of PTSD at 6 months after the acute disease phase, defined by a PTSD Checklist score > 44. Secondary objectives were to investigate risk factors of PTSD in the medical history of patients and characteristics of the disease at the acute phase by the Peritraumatic Dissociative Experience Questionnaire (PDEQ) and Peritraumatic Distress Inventory (PDI) and the degree of impairment on the Sheehan Disability Scale. RESULTS: We initially included 32 of 80 patients admitted during the study period. At 6 months, seven of 30 still followed up had a PTSD Checklist score > 44, suggesting a PTSD prevalence of 23%; 23 (77%) patients had a hydroxyzine prescription at the acute phase. The main risk factors associated with PTSD at 6 months were psychological results at the acute phase. CONCLUSIONS: Despite frequent prescription of hydroxyzine at the acute phase, almost one-quarter of patients with SJS/TEN had PTSD at 6 months. A systematic psychiatric evaluation should be offered regularly for at least 1 year after the acute disease phase.
BACKGROUND: Epidermal necrolysis is a rare and severe cutaneous adverse reaction to drugs with long-term somatic consequences and potentially underrecognized psychological complications. OBJECTIVES: To assess the prevalence and risk factors of post-traumatic stress disorder (PTSD) in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in a population of adults undergoing psychiatric evaluation. METHODS: In this prospective study, we included adult patients admitted at the acute phase of SJS/TEN to our dermatology department from June 2009 to February 2013. The main objective was to assess the prevalence of PTSD at 6 months after the acute disease phase, defined by a PTSD Checklist score > 44. Secondary objectives were to investigate risk factors of PTSD in the medical history of patients and characteristics of the disease at the acute phase by the Peritraumatic Dissociative Experience Questionnaire (PDEQ) and Peritraumatic Distress Inventory (PDI) and the degree of impairment on the Sheehan Disability Scale. RESULTS: We initially included 32 of 80 patients admitted during the study period. At 6 months, seven of 30 still followed up had a PTSD Checklist score > 44, suggesting a PTSD prevalence of 23%; 23 (77%) patients had a hydroxyzine prescription at the acute phase. The main risk factors associated with PTSD at 6 months were psychological results at the acute phase. CONCLUSIONS: Despite frequent prescription of hydroxyzine at the acute phase, almost one-quarter of patients with SJS/TEN had PTSD at 6 months. A systematic psychiatric evaluation should be offered regularly for at least 1 year after the acute disease phase.
Authors: Pauline O'Reilly; Pauline Meskell; Barbara Whelan; Catriona Kennedy; Bart Ramsay; Alice Coffey; Donal G Fortune; Sarah Walsh; Saskia Ingen-Housz-Oro; Christopher B Bunker; Donna M Wilson; Isabelle Delaunois; Liz Dore; Siobhan Howard; Sheila Ryan Journal: PLoS One Date: 2022-06-27 Impact factor: 3.752
Authors: Wan-Chun Chang; Riichiro Abe; Paul Anderson; Wanpen Anderson; Michael R Ardern-Jones; Thomas M Beachkofsky; Teresa Bellón; Agnieszka K Biala; Charles Bouchard; Gianpiero L Cavalleri; Nicole Chapman; James Chodosh; Hyon K Choi; Ricardo R Cibotti; Sherrie J Divito; Karen Dewar; Ulrike Dehaeck; Mahyar Etminan; Diane Forbes; Esther Fuchs; Jennifer L Goldman; James H Holmes; Elyse A Hope; Shuen-Iu Hung; Chia-Ling Hsieh; Alfonso Iovieno; Julienne Jagdeo; Mee Kum Kim; David M Koelle; Mario E Lacouture; Sophie Le Pallec; Rannakoe J Lehloenya; Robyn Lim; Angie Lowe; Jean McCawley; Julie McCawley; Robert G Micheletti; Maja Mockenhaupt; Katie Niemeyer; Michael A Norcross; Douglas Oboh; Cristina Olteanu; Helena B Pasieka; Jonathan Peter; Munir Pirmohamed; Michael Rieder; Hajirah N Saeed; Neil H Shear; Christine Shieh; Sabine Straus; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Sheng-Ying Tsou; Mayumi Ueta; Simona Volpi; Chen Wan; Hongsheng Wang; Zhao-Qing Wang; Jessica Weintraub; Cindy Whale; Lisa M Wheatley; Sonia Whyte-Croasdaile; Kristina B Williams; Galen Wright; Sonia N Yeung; Li Zhou; Wen-Hung Chung; Elizabeth J Phillips; Bruce C Carleton Journal: J Dermatol Sci Date: 2020-03-07 Impact factor: 4.563
Authors: E C Kuijper; L E French; C P Tensen; M H Vermeer; J N Bouwes Bavinck Journal: J Eur Acad Dermatol Venereol Date: 2020-05-15 Impact factor: 6.166
Authors: P O'Reilly; C Kennedy; P Meskell; A Coffey; I Delaunois; L Dore; S Howard; B Ramsay; C Scanlon; D M Wilson; B Whelan; S Ryan Journal: Br J Dermatol Date: 2020-01-11 Impact factor: 9.302